Mylan (MYL) Earnings Preview For Thursday

Background:  Mylan Inc., together with its subsidiaries, engages in the development, manufacture, marketing, licensing, and distribution of generic and branded generic pharmaceuticals, specialty pharmaceuticals, and active pharmaceutical ingredients (APIs) worldwide. It operates in two segments, Generics and Specialty. The company was founded in 1961 and is based in Canonsburg, Pennsylvania. Mylan trades an average of 3.8 million shares per day with a marketcap of $10 billion.

Mylan is anticipated to report good third-quarter earnings Before Market Open on October 25, 2012.

The consensus estimate is currently 77 cents a share, an improvement of 22 cents (28.6%) from 55 cents during the same period last year. Estimates from analysts range from a low of 71 cents per share, up to 81 cents per share.

Over half the analysts covering Mylan rate it as a buy or strong buy. 14 of the 21 analysts covering the company give a buy recommendation. 6 analysts rate it a hold, and 1 recommend selling. New investors from a year ago are happy, and analysts rating this company a buy have called it correctly. The shares have move higher 38% over the last 52 weeks. Analysts are calling for a price target of $27.66.

@paid2Trade